Jeffrey Szymanski

Medicine & Life Sciences

1. Circulating Tumor DNA 100%
2. Cystectomy 75%
3. Residual Neoplasm 73%
4. Messenger RNA 72%
5. Urine 71%
6. Brain Ischemia 69%
7. Urinary Bladder Neoplasms 63%
8. Troponin I 62%
9. Reperfusion 61%
10. Neoplasms 58%
11. Clinical Decision Support Systems 54%
12. Humoral Hypercalcemia Of Malignancy 54%
13. Capillary Malformations, Congenital, 1 53%
14. Photopheresis 51%
15. Liquid Biopsy 51%
16. Neurons 51%
17. Sturge-Weber Syndrome 50%
18. Muscles 50%
19. Cell-Free Nucleic Acids 49%
20. Cohort Studies 47%
21. DNA 46%
22. Troponin 45%
23. Neurofibrosarcoma 44%
24. Galectin 3 44%
25. Vascular Access Devices 42%
26. Whole Genome Sequencing 38%
27. Radiosurgery 36%
28. Hematology 35%
29. Polyribosomes 35%
30. Plexiform Neurofibroma 34%
31. Organelles 31%
32. Brain Natriuretic Peptide 31%
33. Compliance 30%
34. Non-Small Cell Lung Carcinoma 29%
35. Hypercalcemia 29%
36. Parathyroid Hormone-Related Protein 26%
37. Colorectal Neoplasms 26%
38. Catheters 26%
39. Heart Failure 24%
40. Equipment and Supplies 22%
41. Pressure 22%
42. Cross-Sectional Studies 21%
43. Biomarkers 21%
44. Staining and Labeling 21%
45. Arteriovenous Fistula 19%
46. Tumor Burden 18%
47. Genes 17%
48. Uridine 17%
49. Neurofibromatosis 1 16%
50. Adenine 16%